NOS Inhibitor Kit

A collection of popular inhibitors of the nitric oxide synthase isoforms, commonly used for studies of the biochemical and physiological functions of NO.

Product attributes

Storage Conditions	See individual components for storage temperature, Desiccate
CAS number	150403-89-7, 2942-42-9, 36889-13-1, 53308-83-1

Product Description

This kit contains four nitric oxide synthase (NOS) inhibitors: 7-NI (00240) (50 mg), L-NMMA (00241) (25 mg), L-NIL (00242) (5 mg) and L-NIO (00243) (5 mg).

- 7-NI: Selective inhibition of NOS in brain tissues
- L-NMMA: Competitively inhibits NOS in a wide range of cells
- L-NIL: Moderately selective inhibition of iNOS over other NOS isoforms
- L-NIO: Non-selective inhibition of the NOS isoforms

These nitric oxide synthase (NOS) inhibitors are often used to study of nitric oxide (NO) activity in the brain as well as biochemical and physiological functions of NO in a variety of cell types. 7-NI (7-Nitroindazole) is a selective inhibitor for the brain nitric oxide synthase (NOS). L-NMMA (N^G-Methyl-L-arginine, acetate salt) competitively inhibits NOS in a wide range of cells. L-NIL (N^6-(1-Iminoethyl)-lysine, hydrochloride) exhibits about 28-fold greater selectivity (IC_{50} = 3.3 uM) than for the rat brain constitutive enzyme (IC_{50} = 92 uM). It exhibits about 10-fold greater inhibitory potency than NG-monomethyl-L-arginine in inhibiting γ-interferon-induced NO_2- production (IC_{50} = 460 nM). L-NIO (N^5-(1-Iminoethyl)-L-ornithine, dihydrochloride) is a potent, irreversible inhibitor of nitric oxide synthase isoforms.

We also have a selection of dyes and probes for detecting nitric oxide or reactive oxygen in cells.

References

1. Br J Pharmacol, 102(1), 234 (1991), DOI: 10.1111/j.1476-5381.1991.tb12159.x
2. Br J Pharmacol, 107(4), 1159 (1992), DOI: 10.1111/j.1476-5381.1992.tb13423.x
3. Br J Pharmacol 110, 225 (1993), DOI: 10.1111/j.1476-5381.1993.tb13796.x
4. J Med Chem 37, 3886 (1994). DOI: 10.1021/jm00049a007
5. Biochem Biophys Res Comm 205, 992 (1994), DOI: 10.1006/bbrc.1994.2764
6. Meth in Enzymol 268, 393 (1995), DOI: 10.1016/S0076-6879(96)68041-0
7. Stroke 26, 2172 (1995), DOI: 10.1161/01.STR.26.11.2172
8. Eur J Pharmacol 294(2-3), 703 (1995). DOI: 10.1016/0014-2999(95)00618-4
9. Biochem Pharmacol 51(4), 383 (1996), DOI: 0.1016/0006-2952(95)02099-3
10. Am J Physiol 269, E709 (1996), DOI: 10.1152/ajpendo.1996.270.4.E709
11. Alcohol Clin Exp Res 33, 1158 (2009) DOI: j.1530-0277.2009.00939.x
12. Mol Pain 6, 13 (2010), DOI: 10.1186/1744-8069-6-13
13. Nat Med 17, 1619 (2011). DOI: 10.1038/nm.2544
14. Alcohol, 46, 727 (2012), DOI: 10.1016/j.alcohol.2012.09.001
15. Alcohol, 47, 339 (2013), DOI: 10.1016/j.alcohol.2013.03.004
16. PLoS ONE, 8(7): e64837. (2013) DOI: 10.1371/journal.pone.0064837
17. Clin Exp Pharmacol Physiol, 41, 246 (2014), DOI: 10.1111/1440-1681.12207